Abstract
There are no adequate vaccines against some of the new or reemerged infectious scourges such as HIV and TB. They may require strong and enduring cell-mediated immunity to be elicited. This is quite a task, as the only known basis of protection by current commercial vaccines is antibody. As DNA or RNA vaccines may induce both cell-mediated and humoral immunity, great interest has been shown in them. However, doubt remains whether their efficacy will suffice for their clinical realization. We look at the various tactics to increase the potency of nucleic acid vaccines and divided them broadly under those affecting delivery and those affecting immune induction. For delivery, we have considered ways of improving uptake and the use of bacterial, replicon or viral vectors. For immune induction, we considered aspects of immunostimulatory CpG motifs, coinjection of cytokines or costimulators and alterations of the antigen, its cellular localization and its anatomical localization including the use of ligand-targeting to lymphoid tissue. We also thought that mucosal application of DNA deserved a separate section. In this review, we have taken the liberty to discuss these enhancement methods, whenever possible, in the context of the underlying mechanisms that might argue for or against these strategies.
Article PDF
Similar content being viewed by others
References
Wolff JA, Malone RW, Williams P, et al.: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465–1468.
Danko I, Williams P, Herweijer H, et al.: High expression of naked plasmid DNA in muscles of young rodents. Hum Mol Genet 1997;6: 1435–1443.
Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W: Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991;11:474–485
Hartikka J, Bozoukova V, Jones D, et al.: Sodium phosphate enhances plasmid DNA expression in vivo. Gene Ther 2000;7:1171–1182.
Widera G, Austin M, Rabussay D, et al.: Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635–4640.
Bachy M, Boudet F, Bureau M, et al.: Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 2001;19:1688–1693.
Hartikka J, Bozoukova V, Ferrari M, et al.: Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001;19:1911–1923.
Sizemore DR, Branstrom AA, Sadoff JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995;270:299–302.
Pascual DW, Powell RJ, Lewis GK, Hone DM: Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine. Behring Inst Mitt 1997; 98:143–152.
Darji A, Guzman CA, Gerstel B, et al.: Oral somatic transgene vaccination using attenuated S typhimurium. Cell 1997;91: 765–775.
Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM: Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000;6:66–71.
Svensson M, Johansson C, Wick MJ: Salmonella enterica serovar typhimurium-induced maturation of bone marrow-derived dendritic cells. Infect Immun 2000;68: 6311–6320.
Monack DM, Raupach B, Hromockyj AE, Falkow S: Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc Natl Acad Sci USA 1996; 93:9833–9838.
Heath WR, Carbone FR: Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47–64.
Yrlid U, Wick MJ: Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 2000;191: 613–624.
Medina E, Guzman CA, Staendner LH Colombo MP, Paglia P: Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. Eur J Immunol 1999;29: 693–699.
Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP: Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92:3172–3176.
Weiss S, Krusch S: Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells. Biol Chem 2001; 382:533–541.
Tacket CO, Sztein MB, Wasserman SS, et al.: Phase 2 clinical trial of attenuated Salmonella enterica serovar typhioral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000;68: 1196–1201.
Kubori T, Sukhan A, Aizawa SI, Galan JE: Molecular characterization and assembly of the needle complex of the Salmonella typhimurium type III protein secretion system. Proc Natl Acad Sci USA 2000;97:10225–10230.
Froloy I, Hoffman TA, Pragai BM, et al.: Alpha virus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA 1996;93:11371–11377.
Schlesinger S, Dubensky TW: Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 1999;10:434–439.
Khromykh AA, Westaway EG: Subgenomic replicons of the flavivirus Kunjin: construction and applications. J Virol 1997;71: 1497–1505.
Schlesinger S: Alphaviruses—vectors for the expression of heterologous genes. Trends Biotechnol 1993;11:18–22.
Mandl CW, Aberle JH, Aberle SW, Holzmann H, Allison SL, Heinz FX: In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 1998;4:1438–1440.
Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D: Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997; 15:763–767.
Ying H, Zaks TZ, Wang RF, et al.: Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999;5:823–827.
Dubensky TW, Liu MH, Ulmer JB: Delivery Systems for Gene-based Vaccines. Molecular Medicine 2000;6:723–732.
Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP: Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 2000;60:51–55.
Dubensky TW, Jr., Driver DA, Polo JM, et al.: Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 1996;70:508–519.
Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P: Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 1998;16:562–565.
Fleeton MN, Liljestrom P, Sheahan BJ, Atkins GJ: Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. Journal of General Virology 2000;81:749–758.
Hariharan MJ, Driver DA, Townsend K, et al.: DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 1998;72:950–958.
Cheng WF, Hung CF, Chai CY, et al.: Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. Journal of Immunology 2001;166: 6218–6226.
Leitner WW, Ying H, Restifo NP: DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 2000;18:765–777.
Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ: Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol 1997;78:1559–1563.
Kohno A, Emi N, Kasai M, Tanimoto M, Saito H: Semliki Forest virus-based DNA expression vector: transient protein production followed by cell death. Gene Ther 1998;5:415–418.
Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature 1998;392:86–89.
Morris-Downes MM, Phenix KV, Smyth J, et al.: Semliki Forest Virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 2001;19:1978–1988.
Learmont JC, Geczy AF, Mills J, et al.: Immunologic and Virologic Status after 14 to 18 Years of Infection with an Attenuated Strain of HIV-1—A Report from the Sydney Blood Bank Cohort. N Engl J Med 1999;340:1715–1722.
Cairns JS, Sarver N: New viral vectors for HIV vaccine delivery. AIDS Res Hum Retroviruses 1998;14:1501–1508.
Hu SL, Travis BM, Stallard V, et al.: Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection. Aids Res Hum Retroviruses 1992;8:1489–1494.
Gurvich EB: The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine. Vaccine 1992;10:96–97.
Benson J, Chougnet C, Robert-Guroff M, et al.: Recombinant vaccine-induced protection against the highly pathogenic SIV mac 251: dependence on route of challenge exposure. J Virol 1998; 72:4170–4182.
Shen L, Chen ZW, Miller MD, et al.: Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440–443.
Cooney EL, McElrath MJ, Corey L., et al.: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gpl60 protein. Proc Natl Acad Sci USA 1993; 90:1882–1886.
Cooney EL, Collier AC, Greenberg PD, et al.: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567–572.
Corey L, McElrath MJ, Weinhold K, et al.: Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:301–309.
Egan MA, Pavlat WA, Tartaglia J, et al.: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-IMN env gene. J Infect Dis 1995;171: 1623–1627.
Lubeck MD, Natuk R, Myagkikh M, et al.: Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997;3: 651–658.
Yasutomi Y, Koenig S, Haun SS, et al.: Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993;150:3101–3107.
Leong KH, Ramsay AJ, Morin MJ, Robinson HL, Boyle DB, Ramshaw IA: Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowl pox viruses. In: Brown F, Chanock H, Norrby E, eds. Vaccines 95: Cold Spring Harbour Laboratory Press, 1995: 327–331.
Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA: Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowl pox virus. J Virol 1998;72: 10180–10188.
Schneider J, Gilbert SC, Blanchard TJ, et al.: Enhanced immunogenicity for CD8+T cell induction and complete protective efficacy boosting with modified vaccinia virus Ankara. Nat Med 1998; 4:397–402.
Robinson HL, Montefiori DC, Johnson RP, et al.: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Med 1999;5:526–534.
Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by amultiprotein DNA/MVA vaccine. Science 2001;292:69–74.
Allen TM, Vogel TU, Fuller DH, et al.: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164:4968–4978.
Boyle JS, Silva A, Brady JL, Lew AM: DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci USA 1997; 94:14626–14631.
Ramshaw IA, Ramsay AJ: The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000;21: 163–165.
Kundig TM, Kalberer CP, Hengartner H, Zinkemagel RM: Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11: 1154–1158.
Murata K, Garcia-Sastre A, Tsuji M, et al.: Characterization of in vivo primary and secondary CD8+T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996;173: 96–107.
Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89: 1595–1601.
Letvin NL, Montefiori DC, Yasutomi Y, et al.: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997; 94:9378–9383.
Song MKL, S.W., Suh, Y.S., Lee, K.J., Sung, Y.C.: Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunisation with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J. Virology 2000;74:2920–2925.
Ramsay AJ, Leong KH, Ramshaw IA: DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol 1997;75:382–388.
Sedegah M, Jones TR, Kaur M, et al.: Boosting with recombinant vaccina increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998;95:7648–7653.
Hanke T, Samuel RV, Blanchard TJ, et al.: Effective induction of simian immuno-deficiency virus-specific cytotoxic T lymphocytes in macaques by using a multi-epitope gene and DNA primemodified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524–7532.
Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC: Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000;18:2015–2022.
Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM: Modulation of cellular and humoral immune responses to a multi-epitopic HIV-1 DNA vaccine by interleukin-18DNA immunization/viral protein boost. Vaccine 2001; 19:2803–2811.
Fazekasde StG, Webster RG: Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med 1966;124:331–345.
Klenerman P, Zinkernagel RM: Original antigenics in impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998;394:482–485.
Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus ME, Prince AM: DNA prime-canary pox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis 2000;182:18–27.
Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AV: Genegun intradermal DNA immunization followed by boosting with modified vaccinia virus Anakara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 2000;18:623–632.
Fensterle J, Grode L, Hess J, Kaufmann SH: Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J Immunol 1999;163: 4510–4518.
Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL: A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999;17: 1567–1572.
Ulmer JB, DeWitt CM, Chastain M, et al.: Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999;18:18–28.
Krieg AM, Yi AK, Matson S, et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546–549.
Hartmann G, Weiner GJ, Krieg AM: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999;96: 9305–9310.
Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879–2883.
Hemmi H, Takeuchi O, Kawai T, et al.: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740–745.
Pisetsky DS: Immune activation by bacterial DNA: a new genetic code. Immunity 1996;5:303–310.
Roman M, Martin-Orozco E, Goodman JS, et al.: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849–854.
Tascon RE, Ragno S, Lowrie DB, Colston MJ: Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+T cells. Immunology 2000;99:1–7.
Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K: CpG-oligodeoxy nucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999;29:1209–1218.
Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H: CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 2000;164:2372–2378.
Davila E, Celis E: Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor Activity. J Immunol 2000;165: 539–547.
Weeratna RD, McCluskie MJ, Xu Y, Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000;18:1755–1762.
Oehen S, Junt T, Lopez-Macias C, Kramps TA: Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA. Immunology 2000;99: 163–169.
Sato Y, Roman M, Tighe H, et al.: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352–354.
Klinman DM, Yamshchikov G, Ishigatsubo Y: Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635–3639.
Klinman DM, Barnhart KM, Conover J: CpG motifs as immune adjuvants. Vaccine 1999;17: 9–25.
Krieg AM, Wu T, Weeratna R, et al.: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Nalt Acad Sci USA 1998;95: 12631–12636.
Kim JJ, Bagarazzi ML, Trivedi N, et al.: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997;15:641–646.
Bronte V, Tsung K, Rao JB, et al.: IL-2 enhances the function of recombinant pox virus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282–5292.
Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486–492.
Kim JJ, Ayyavoo V, Bagarazzi ML, et al.: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997;158:816–826.
Tsuji T, Hamajima K, Fukushima J, et al.: Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997;158:4008–4013.
Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT: Vaccination with Allergen-IL-18 Fusion DNA protects Against, and Reverses Established, Airway Hyperreactivity in a Murine Asthma Model. J Immunol 2001;166:959–965.
Lu Y, Xin KQ, Hamajima K, et al.: Macrophage inflammatory protein-1 alpha (MIP-1 alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999;115:335–341.
Kim JJ, Yang J, Manson KH, Weiner DB: Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 2001;19: 2496–2505.
Xiang Z, Ertl HC: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2: 129–135.
Gherardi MM, Ramirez JC, Esteban M: Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000;74: 6278–6286.
Haddad D, Ramprakash J, Sedegah M, et al.: Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000;165:3772–3781.
Doe B, Selby M, Barnett S, Baenziger J, Walker CM: Induction of cytotoxic T lymphocytes by intra-muscular immunization with plasmid DNA is facilitated by bone marrow derived cells. Proceedings of the Natinal Academy of Science 1996;93:8578.
Corr M, von Damm A, Lee DJ, Tighe H: In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999;163:4721–4727.
Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH: The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997;159:11–14.
Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA: Generation of MHC class 1-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996;89: 59–67.
Conry RM, Widera G, LoBuglio AF, et al.: Selected strategies to augment polynucleotide immunization. Gene Ther 1996;3:67–74.
Iwasaki A, Stiemholm BJ, Chan AK, Berinstein NL, Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158:4591–4601.
Chan K, Lee DJ, Schubert A, et al.: The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J Immunol 2001;166:3061–3066.
Santra S, Barouch DH, Jackson SS, et al.: Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J Immunol 2000; 165:6791–6795.
Mellman I, Turley SJ, Steinman RM: Antigen processing for amateurs and professionals. Trends Cell Biol 1998;8:231–237.
Gurunathan S, Irvine KR, Wu CY, et al.: CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998;161:4563–4571.
Mendoza RB, Cantwell MJ, Kipps TJ: Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 1997;159:5777–5781.
Jallet C, Jacob Y, Bahloul C, et al.: Chimeric lyssa virus glycoproteins with increased immunological potential. J Virol 1999;73: 225–233.
Rodriguez F, An LL, Harkins S, et al.: DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 1998;72:5174–5181.
Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP: Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res 1994;54: 4155–4161.
Whitton JL, Sheng N, Oldstone MB, McKee TA: A “string-of-beads” vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol 1993;67:348–352.
Thomson SA, Sherritt MA, Medveczky J, et al.: Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 1998;160:1717–1723.
Hanke T, Schmeider J, Gilbert SC, Hill AV, McMichael A: DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998; 16:426–435.
Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL: Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996;183:1739–1746.
Boyle JS, Koniaras C, Lew AM: Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997;9:1897–1906.
Inchauspe G, Vitvitski L, Major ME, et al.: Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16:185–195.
Svanholm C, Bandholtz L, Lobell A, Wigzell H: Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion. J Immunol Methods 1999; 228:121–130.
Bucht G, Sjolander KB, Eriksson S, Lindgren L, Lundkvist A, Elgh F: Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. Vaccine 2001;19:3820–3829.
Li M, Davey GM, Sutherland RM, et al.: Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166: 6099–6103.
Raz E, Carson DA, Parker SE, et al.: Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994;91:9519–9523.
Feltquate DM, Heaney S, Webster RG, Robinson HL: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158:2278–2284.
Kawabata S, Terao Y, Fujiwara T, Nakagawa I, Hamada S: Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect Immun 1999;67:5863–5868.
Zhang G, Budker V, Williams P, Subbotin V, Wolff JA: Efficient expression of naked dna delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 2001;12:427–438.
Gerloni M, Billetta R, Xiong S, Zanetti M: Somatic transgene immunization with DNA encoding an immunoglobulin heavy chain. DNA Cell Biol 1997;16:611–625.
Boyle JS, Barr IG, Lew AM: Strategies for improving responses to DNA vaccines. Mol Med 1999; 5:1–8.
Moonsom S, Khunkeawla P, Kasinrerk W: Production of polyclonal and monoclonal antibodies against CD54 molecules by intrasplenic immunization of plasmid DNA encoding CD54 protein. Immunol Lett 2001;76:25–30.
Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, Oehen S, Kundig TM: Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001;98:3299–3303.
Boyle JS, Brady JL, Lew AM: Enhanced responses to a DNA vaccineencodinga fusion antigen that is directed to sites of immune induction. Nature 1998;392:408–411.
Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM: A fusion DNA vaccine that targets antigen-presenting cells increasesprotection from viral challenge. Proc Natl Acad Sci USA 2000;97:6676–6680.
Huang TH, Wu PY, Lee CN, Huang HI, Hsieh SL, Kung J, Tao MH: Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen. Blood 2000;96:3663–3670.
Chaplin PJ, De Rose R, Boyle JS, McWaters P, Kelly J, Tennent JM, Lew AM, Scheerlinck JP: Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudo tuberculosis in sheep. Infect Immun 1999;67:6434–6438.
Lew AM, Brady BJ, Boyle BJ: Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions. Vaccine 2000; 18:1681–1685.
Asakura Y, Hinkula J, Leandersson AC, Fukushima J, Okuda K, Wahren B: Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 1997;46:326–330.
Sagodira S, Iochmann S, Mevelec MN, Dimier-Poisson I, Bout D: Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses. Parasite Immunol 1999;21:507–516.
Fyran EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478–11482.
McCluskie MJ, Davis HL: Mucosal immunization with DNA vaccines. Microbes Infect 1999;1:685–698.
Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B: Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 1999;17:2036–2042.
Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, Walcott S, Gough G: Intraepithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 2001;19:2783–2792.
Sato Y, Saito A, Shishido H, et al. Injection of plasmid DNA into the gastric mucosa induces mucosal and systemic immunity. Cell Immunol 2000;199:58–63.
Chen SC, Fynan EF, Greenberg HB, Herrmann JE: Immunity obtained by gene-gun inoculation of a rotavirus DNA vaccine to the abdominal epidermis or anorectal epithelium. Vaccine 1999;17:3171–3176.
Chen SC, Jones DH, Fynan EF, et al.: Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998;72:5757–5761.
Livingston JB, Lu S, Robinson H, Anderson DJ: Immunization of the female genital tract with a DNA-based vaccine. Infect Immun 1998;66:322–329.
Lunn DP, Soboll G, Schram BR, et al.: Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 1999;17:2245–2258.
Loehr BI, Willson P, Babiuk LA, van Drunen Littel-van den H: Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol 2000; 74:6077–6086.
Schreckenberger C, Sethurathi P, Kanjanahaluethai A, et al.: Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 2000;19:227–233.
Daheshia M, Kuklin N, Manickan E, Chun S, Rouse BT: Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine 1998;16:1103–1110.
Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D: Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997;78:1577–1580.
Winchell JM, Routray S, Betts PW, Van Kruiningen HJ, Silbart LK: Mucosal and systemic antibody responses to a C4/V3 construct following DNA vaccination of rabbits via the Peyer’s patch. J Infect Dis 1998;178:850–853.
Orson FM, Kinsey BM, Hua PJ, Bhogal BS, Densmore CL, Barry MA: Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses. J Immunol 2000;164:6313–6321.
Mannino RJ, Canki M, Feketeova E, et al.: Targeting immune response induction with cochleate and liposome induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev 1998;32:273–287.
Klavinskis LS, Barnfield C, Gao L, Parker S: Intranasal immunization with plas mid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999;162:254–262.
Klavinskis LS, Gao L, Barnfield C, Lehner T, Parker S: Mucosal immunization with DNA-liposome complexes. Vaccine 1997;15:818–820.
Sha Z, Vincen MJ, Compans RW: Enhancement of mucosal immune resporses to the influenza virus HA protein by alternative approaches to DNA immunization. Immumobilogy 1999;200:21–30.
Okada E, Sasaki S, Ishii N, et al.: Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638–3647.
Vadolas J, Davies JK, Wright PJ, Strugnell RA: Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol 1995; 25:969–975.
Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH: Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal anti body responses to encoded protein after oral administration. Vaccine 1997;15:814–817.
Mathiowitz E, Jacob JS, Jong YS, et al.: Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386:410–414.
Mittal SK, Aggarwal N, Sailaja G, et al.: Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000; 19:253–263.
Frey A, Neutra MR: Targeting of mucosal vaccines to Peyer’s patch M cells. Behring Inst Mitt 1997:376–389.
Ennak TH, Giamasca PJ: Microparticle targeting to M cells. Adv Drug Deliv Rev 1998;34:261–283.
Fisher KD, Ulbrich K, Subr V, et al.: A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression. Gene Ther 2000; 7:1337–1343.
Lian T, Bui T, Ho RJ: Formulation of HIV-envelopeprotein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses. Vaccine 1999;18:604–611.
Lycke N, Tsuji T, Holmgren J: The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyl transferase activity. Eur J Immunol 1992;22:2277–2281.
Ban EM, van Ginkel FW, Simecka JW, Kiyono H, Robinson HL, McGhee JR: Mucosal immunization with DNA encoding influenza hemagglutinin. Vaccine 1997;15:811–813.
Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT: Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 1997; 71:3138–3145.
Sasaki S, Hamajima K, Fukushima J, et al.: Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphory 1 lipid A adjuvant vaccine. Infect Immun 1998;66:823–826.
Sasaki S, Sumino K, Hamajima K, et al.: Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine fomulated with QS-21 saponin adjuvant via intramuscular and intrarasal routes. J Virol 1998;72:4931–4939.
Medina E, Guzman CA: Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001;19:1573–1580.
Jones BD, Ghori N, Falkow S: Salmonella typhimurium initiates murine infection by penetratingand destroying the specialized epithelial M cells of the Peyer’s patches. J Exp Med 1994;180:15–23.
Tilney LG, Portnoy DA: Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol 1989;109:1597–1608.
Fernandez-Prada CM, Hoover DL, Tall BD, Hartman AB, Kopelowitz J, Venkatesan MM: Shigella flexneri IpaH(7.8) facilitates escapeofvirulent bacteria from the endocytic vacuoles of mouse and human macrophages. Infect Immun 2000;68:3608–3619.
Darji A, zur Lage S, Garbe AI, Chakraborty T, Weiss S: Oraldelivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol 2000;27:341–349.
Woo PC, Wong L, Zheng B, Yuen K: Unique immunogenicity of hepatitis B virus DNA vaccinepresented by live-attenuated Salmonella typhimurium. Vaccine 2001;19:2945–2954.
Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR: Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 1999;162:1603–1610.
Sizemore DR, Branstrom AA, Sadoff JC: Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 1997;15:804–807.
Dietrich G, Bubert A, Gentschev I, et al.: Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocy to genes. Nat Biotechnol 1998;16:181–185.
Eo SK, Gierynska M, Kamar AA, Rouse BT: Prime-boost immunization withdna vaccine: mucosal route of administration changes the rules. J Immunol 2001;166:5473–5479.
Belyakov IM, Moss B, Strober W, Berzofsky JA: Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999;96:4512–4517.
Tang DC, DeVit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152–154.
Hilleman MR: Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol 1993;18:S5–10.
Eo SK, Lee S, Chun S, Rouse BT: Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J Virol 2001;75:569–578.
Xin KQ, Lu Y, Hamajima K, et al.: Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999;92:90–96.
Xin KQ, Hamajima K, Sasaki S, et al.: IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999;17:858–866.
Xin KQ, Hamajima K, Sasaki S, et al.: Intransal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 1998; 94:438–444.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McKenzie, B.S., Corbett, A.J., Brady, J.L. et al. Nucleic acid vaccines. Immunol Res 24, 225–244 (2001). https://doi.org/10.1385/IR:24:3:225
Issue Date:
DOI: https://doi.org/10.1385/IR:24:3:225